Your fact-checks will appear here
The efficacy and safety of lecanemab and donanemab in slowing cognitive decline in patients with Alzheimer's disease.
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
Two monoclonal antibodies—lecanemab and donanemab—have randomized-trial evidence of modest slowing of cognitive decline at 18 months and emerging longer-term data for lecanemab suggesting continued, s...
The randomized trials of lecanemab and donanemab showed statistically significant slowing of cognitive and functional decline over 18 months, but the absolute differences were small versus placebo and...